-
2
-
-
45149128290
-
Current perspectives on stability of protein drug products during formulation, fill and finish operations
-
Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 2008;24: 504-14.
-
(2008)
Biotechnol Prog
, vol.24
, pp. 504-514
-
-
Rathore, N.1
Rajan, R.S.2
-
3
-
-
33947660965
-
Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes
-
Sharma B. Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv 2007;25:325-31
-
(2007)
Biotechnol Adv
, vol.25
, pp. 325-331
-
-
Sharma, B.1
-
4
-
-
3042780397
-
Current and future considerations for the new classes of biologicals
-
Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm 2004;61:695-708.
-
(2004)
Am J Health Syst Pharm
, vol.61
, pp. 695-708
-
-
Kleinberg, M.1
Mosdell, K.W.2
-
5
-
-
77950877204
-
Application of near-infrared (NIR) spec-troscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein
-
Kirdar AO, Chen G, Weidner J, et al. Application of near-infrared (NIR) spec-troscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Prog 2010;26:527-31
-
(2010)
Biotechnol Prog
, vol.26
, pp. 527-531
-
-
Kirdar, A.O.1
Chen, G.2
Weidner, J.3
-
6
-
-
79551563213
-
Comparability assessments of process and product changes made during development of two different monoclonal antibodies
-
Lubiniecki A, Volkin DB, Federici M, et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 2011;39:9-22.
-
(2011)
Biologicals
, vol.39
, pp. 9-22
-
-
Lubiniecki, A.1
Volkin, D.B.2
Federici, M.3
-
7
-
-
34547637286
-
Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic protein
-
Luo Y, Chen G. Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Bioeng 2007;97:1654-9.
-
(2007)
Biotechnol Bioeng
, vol.97
, pp. 1654-1659
-
-
Luo, Y.1
Chen, G.2
-
8
-
-
77954937558
-
Summary of DIA Workshop: Comparability challenges: Regulatory and scientific issues in the assessment of biopharmaceu-ticals
-
Lewis RM, Cosenza ME. Summary of DIA Workshop: Comparability challenges: Regulatory and scientific issues in the assessment of biopharmaceu-ticals. Drug Inf J 2010;44:485-504.
-
(2010)
Drug Inf J
, vol.44
, pp. 485-504
-
-
Lewis, R.M.1
Cosenza, M.E.2
-
9
-
-
77956873702
-
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies
-
Putnam WS, Prabhu S, Zheng Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010;28:509-16.
-
(2010)
Trends Biotechnol
, vol.28
, pp. 509-516
-
-
Putnam, W.S.1
Prabhu, S.2
Zheng, Y.3
-
10
-
-
84862542513
-
-
Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) [Last accessed 19 December 2011]
-
Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 1996. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm [Last accessed 19 December 2011]
-
Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products
, vol.1996
-
-
-
11
-
-
75649144138
-
-
Rockville, MD: FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER) [Last accessed 19 December 2011]
-
Q5E Comparability of biotechnological/biological products subject to changes in their manufacturing process. Rockville, MD: FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER), 2005. Available at: http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/ucm128076.pdf [Last accessed 19 December 2011]
-
(2005)
Q5E Comparability of Biotechnological/biological Products Subject to Changes in Their Manufacturing Process
-
-
-
12
-
-
84862541885
-
-
International Conference on Harmonization/ICH Expert Working Group [Last accessed 9 March 2012]
-
Comparability of biotechnological/biological products subject to changes in their manufacturing process, Q5E. International Conference on Harmonization/ICH Expert Working Group 2004. Available at: http://www.i-ch.org/ fileadmin/Public/Web/Site/ICH/Products/Guidelines/Quality/Q5E/Step4/Q5E/ Guideline.pdf [Last accessed 9 March 2012]
-
(2004)
Comparability of Biotechnological/biological Products Subject to Changes in Their Manufacturing Process, Q5E
-
-
-
13
-
-
84862557851
-
-
Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) [Last accessed 19 December 2011]
-
Avonexs Summary Basis for Approval. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2004. Available at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm086056.pdf [Last accessed 19 December 2011]
-
(2004)
Avonex Summary Basis for Approval
-
-
-
14
-
-
84856542980
-
-
London: European Medicines Agency[Last accessed 16 March 2012]
-
Raptiva European Public Assessment Report Scientific Discussion. London: European Medicines Agency, 2004. Available at: http://www.ema.europa.eu/docs/en/ GB/document/library/EPAR/-/Scientific/Discussion/human/000542/WC500057849.pdf [Last accessed 16 March 2012]
-
(2004)
Raptiva European Public Assessment Report Scientific Discussion
-
-
-
16
-
-
33644952525
-
-
London: European Medicines Agency [Last accessed 19 December 2011)
-
Guideline on similar biological medicinal products. London: European Medicines Agency 2005. Available at: http://www.emea.europa.eu/pdfs/human/ biosimilar/043704en.pdf [Last accessed 19 December 2011)
-
(2005)
Guideline on Similar Biological Medicinal Products
-
-
-
17
-
-
34548168792
-
EMEA guidelines on biosimilars and their clinical implications
-
Rossert J. EMEA guidelines on biosimilars and their clinical implications. Kidney Blood Press Res 2007;30(Suppl1):13-17.
-
(2007)
Kidney Blood Press Res
, vol.30
, Issue.SUPPL. 1
, pp. 13-17
-
-
Rossert, J.1
-
18
-
-
84860314070
-
-
Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) [Last accessed 6 March 2012]
-
Scientific Considerations in Demonstrating Biosimilarity to a Reference Protein Product; Draft Guidance; 9 February 2012. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2012. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Last accessed 6 March 2012]
-
(2012)
Scientific Considerations in Demonstrating Biosimilarity to A Reference Protein Product; Draft Guidance; 9 February 2012
-
-
-
19
-
-
79955655456
-
Biosimilars 2.0: Guiding principles for a global 'patients first' standard
-
Miletich J, Eich G, Grampp G, et al. Biosimilars 2.0: Guiding principles for a global 'patients first' standard. MAbs 2011;3:318-25.
-
(2011)
MAbs
, vol.3
, pp. 318-325
-
-
Miletich, J.1
Eich, G.2
Grampp, G.3
-
20
-
-
69449095403
-
Biosimilar therapeutics-what do we need to consider?
-
Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009;2:i27-36
-
(2009)
NDT Plus
, vol.2
-
-
Schellekens, H.1
-
21
-
-
84855436897
-
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin- A (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, double-blind study
-
Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77:8-17.
-
(2012)
Clin Nephrol
, vol.77
, pp. 8-17
-
-
Haag-Weber, M.1
Eckardt, K.U.2
Hörl, W.H.3
-
22
-
-
79952749322
-
Biosimilar agents in oncology/haematology: From approval to practice
-
Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: From approval to practice. Eur J Haematol 2010;86:277-88.
-
(2010)
Eur J Haematol
, vol.86
, pp. 277-288
-
-
Niederwieser, D.1
Schmitz, S.2
-
23
-
-
52649084303
-
Recombinant human erythropoietins, biosimilars and immunogenicity
-
Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 2008;21:497-502.
-
(2008)
J Nephrol
, vol.21
, pp. 497-502
-
-
Schellekens, H.1
-
24
-
-
67349221747
-
Assessing the bioequivalence of biosimilars: The Retacrit case
-
Schellekens H. Assessing the bioequivalence of biosimilars: The Retacrit case. Drug Discov Today 2009;14:495-9.
-
(2009)
Drug Discov Today
, vol.14
, pp. 495-499
-
-
Schellekens, H.1
-
25
-
-
84881443667
-
-
London: European Medicines Agency 2006 [Last accessed 16 March 2012]
-
Refusal assessment reportfor Alpheon. London: European Medicines Agency 2006. Available at: http://www.ema.europa.eu/docs/en/GB/document/li-brary/EPAR/- /Public/assessment/sreport/human/000585/WC500070792.pdf [Last accessed 16 March 2012]
-
Refusal Assessment Reportfor Alpheon
-
-
-
26
-
-
84946542353
-
-
London: European Medicines Agency [Last accessed 16 March 2012]
-
Withdrawal assessment for Insulin Human Rapid Marvel. London: European Medicines Agency, 2008. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/Application/withdrawal/assessment/report/2010/01/WC500067086. pdf [Last accessed 16 March 2012]
-
(2008)
Withdrawal Assessment for Insulin Human Rapid Marvel
-
-
-
27
-
-
84946542353
-
-
London: European Medicines Agency[Last accessed 16 March 2012]
-
Withdrawal assessment for Insulin Human Long Marvel. London: European Medicines Agency, 2008. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/Application/withdrawal/assessment/report/2010/01/WC500067170. pdf[Last accessed 16 March 2012]
-
(2008)
Withdrawal Assessment for Insulin Human Long Marvel
-
-
-
28
-
-
84862541886
-
-
London: European Medicines Agency 2008 [Last accessed 16 March 2012]
-
Withdrawal assessment for Insulin Human 30/70 Marvel. London: European Medicines Agency 2008. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/Application/withdrawal/assessment/report/2010/01/WC500067169. pdf [Last accessed 16 March 2012]
-
Withdrawal Assessment for Insulin Human 30/70 Marvel
-
-
-
29
-
-
84856808079
-
-
London: European Medicines Agency[Last accessed 16 March 2012]
-
Omnitrope® European Public Assessment Report Scientific Discussion. London: European Medicines Agency, 2006. Available at: http://www.ema. europa.eu/docs/en/GB/document/library/EPAR/-/Scientific/Discussion/human/000607/ WC500043692.pdf [Last accessed 16 March 2012]
-
(2006)
Omnitrope European Public Assessment Report Scientific Discussion
-
-
|